Kyverna Therapeutics (KYTX) News Today

Kyverna Therapeutics, Inc. (NASDAQ: KYTX) saw volatile trading after releasing encouraging one-year data for miv-cel, its investigational CAR T-cell therapy for stiff person syndrome (SPS) and generalized myasthenia gravis (gMG). The stock initially increased on the results but later reversed those gains as investors weighed the limited sample sizes, development timeline and commercialization risks.

• Positive Sentiment: In the 26-patient KYSA-8 SPS trial, improvements in walking ability and other disease measures remained significant after 12 months. Ninety-five percent of patients who achieved a clinically meaningful walking improvement maintained it, 67% of patients who previously needed walking aids remained independent, and 92% stayed off chronic immunotherapies. Kyverna one-year miv-cel data
• Positive Sentiment: Longer-term gMG results also showed durable responses: all seven patients achieved clinically meaningful improvements at 24 weeks, with benefits sustained for at least one year in the five patients reaching that follow-up. Six of seven remained off immunosuppressive therapy at their latest assessment. No high-grade cytokine release syndrome, ICANS or IEC-HS was reported. One-year benefits sustain momentum
• Positive Sentiment: Kyverna said its rolling Biologics License Application for SPS remains on track for completion in the fourth quarter of 2026, supporting the potential for miv-cel to become the first approved SPS treatment and an early CAR T therapy for autoimmune disease.
• Neutral Sentiment: Management argued that the severe disease burden and potential to eliminate chronic treatment could support premium pricing. However, pricing, reimbursement and regulatory approval remain uncertain, and the company is still pre-commercial.
• Negative Sentiment: The evidence remains based on very small, single-arm groups—26 SPS patients and seven gMG patients—while the gMG Phase 3 trial is not expected to complete enrollment until mid-2027. These factors likely contributed to profit-taking after the initial rally. KYTX stock reverses gains